動脈瘤性くも膜下出血治療薬市場：薬物クラス別（オピオイド鎮痛剤、カルシウム拮抗剤、抗けいれん剤、便軟化剤、浸透圧剤/利尿剤、その他の薬物）。世界の機会分析および産業予測、2020-2030年

Aneurysmal Subarachnoid Hemorrhage Drugs Market By Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics, Other Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

動脈瘤性くも膜下出血治療薬の世界市場は、2020年に3億2351万ドル、2021年から2030年にかけてCAGR3.6%を記録し、2030年には4億5631万ドルに達すると予測されます。動脈瘤性くも膜下出血（aSAH）は、脳動脈瘤が... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年5月31日	US$5,769 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	180	英語

サマリー

動脈瘤性くも膜下出血治療薬の世界市場は、2020年に3億2351万ドル、2021年から2030年にかけてCAGR3.6%を記録し、2030年には4億5631万ドルに達すると予測されます。
動脈瘤性くも膜下出血（aSAH）は、脳動脈瘤が破裂し、くも膜下腔に出血が起こる疾患です。重症の場合、出血により脳が損傷し、麻痺、昏睡、あるいは死に至ることもあります。米国国立衛生研究所（NIH）は、aSAHは世界的な健康問題であり、高い致死率と後遺症率を有すると述べています。
aSAHの主な症状は、激しい頭痛、吐き気、嘔吐、肩こり、羞明、かすみ目、意識消失、発作などです。aSAHの診断プロセスには、コンピュータ断層撮影（CT）、腰椎穿刺、血管造影、磁気共鳴画像法（MRI）などがあります。
aSAHの世界市場を牽引する主な要因は、脳卒中や高血圧などの疾患の有病率の上昇、老年人口の急増です。また、アルコール摂取量の増加や喫煙などのライフスタイルがaSAHのリスクを高め、それが市場の成長を促進しています。しかし、aSAHの治療中に消費される薬物や薬剤の副作用が、市場の成長を抑制しています。さらに、aSAHの治療に関する意識の高まりは、将来的に市場成長のための多くの機会を提供することが期待されます。
aSAH市場は、薬物クラスと地域に基づいてセグメント化されています。薬物クラスに基づいて、市場はオピオイド鎮痛剤、カルシウム拮抗剤、抗痙攣剤、便軟化剤、浸透圧剤/利尿剤、その他の薬剤に区分されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。
薬剤の種類別では、カルシウム拮抗薬が市場を席巻しており、心血管疾患の有病率上昇、ライフスタイルの変化、高血圧の増加により、予測期間中もこの傾向が続くと予想されます。また、不安障害や双極性障害を持つ人々への支援の高まりも、動脈瘤性くも膜下出血治療薬市場の成長に貢献すると期待されます。また、患者の意識レベルの向上、治療オプションの可用性と脆弱な老人の人口は、カルシウムチャネルブロッカーaSAH薬市場の成長を推進する影響要因のいくつかである。
地域別では、北米が2020年の市場を独占しました。これは、先進的なaSAH治療薬へのアクセスを容易にする良好な医療インフラがあるためです。また、精密医療や医療費負担適正化法などの政府の取り組みや、計画的な償還政策が北米の市場成長に貢献しました。さらに、人々の意識の高まりと高い購買意欲が、これらの機器に対する需要を高めています。しかし、アジア太平洋地域は、医療インフラ強化のための政府支援の増加により、予測期間中にかなりの市場成長を目撃すると予想されます。インドや中国など、可処分所得が高い国々の経済発展が製品需要を促進しています。
世界のaSAH治療薬市場で事業を展開している主要企業は、Azurity Pharmaceuticals、Johnson & Johnson、MediCure、NeurOp、Orexo AB、Pfizer、Inc、Pharmaxis、Ltd、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltd、およびVitrais、Inc.であります。これらの企業は、主要な開発戦略として、製品の発売、コラボレーション、M&Aを採用しました。

ステークホルダーにとっての主な利点
本レポートは、差し迫った投資ポケットを解明するために、現在のトレンドと将来の予測とともに、世界のASAH医薬品の市場規模に関する詳細な分析を提供します。
2021年から2030年までの市場分析を提供しており、利害関係者が市場の優勢な機会を活用することを可能にすると期待されます。
地域に関する包括的な分析は、地域市場を理解し、戦略的な事業計画を促進し、優勢な機会を決定するのに役立ちます。
主要企業のプロファイルと成長戦略を徹底的に分析し、ASAH Drugsの世界市場成長の競争展望を理解することができます。
主要市場セグメント
#薬物クラス別
#オピオイド鎮痛剤
##カルシウム拮抗薬
## 抗けいれん薬
##便軟化剤
##浸透圧剤/利尿剤
##その他の医薬品
#地域別
##北アメリカ
###米国
###カナダ
###メキシコ
##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###スペイン
###その他のヨーロッパ
##アジア・パシフィック
###日本
###中国
###オーストラリア
###インド
###韓国
###その他のアジア太平洋地域
##ラムエア
###ブラジル
###サウジアラビア
###南アフリカ
###LAMEAの残りの地域
本レポートで紹介されている主要企業のリスト
- アズキュリティー・ファーマシューティカルズ
- ジョンソン・エンド・ジョンソン
- メディキュア
- NeurOp
- オレキソAB
- ファイザー株式会社
- ファーマクシス・リミテッド
- サンファーマシューティカルインダストリー株式会社
- テバ・ファーマシューティカル・インダストリーズ
- ヴィトライス・インク

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Opioid Analgesic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Calcium Channel Blocker
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Anticonvulsant
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Stool Softener
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Osmotic Agents/Diuretics
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Other Drugs
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Drug Class
5.2.3 North America Market size and forecast, by country
5.2.3.1 U.S.
5.2.3.1.1 Market size and forecast, by Drug Class
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Drug Class
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Drug Class
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Drug Class
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Drug Class
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Drug Class
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Drug Class
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Drug Class
5.3.3.5 Rest of Europe
5.3.3.5.1 Market size and forecast, by Drug Class
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Drug Class
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 Japan
5.4.3.1.1 Market size and forecast, by Drug Class
5.4.3.2 China
5.4.3.2.1 Market size and forecast, by Drug Class
5.4.3.3 Australia
5.4.3.3.1 Market size and forecast, by Drug Class
5.4.3.4 India
5.4.3.4.1 Market size and forecast, by Drug Class
5.4.3.5 Rest of Asia-Pacific
5.4.3.5.1 Market size and forecast, by Drug Class
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Drug Class
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Drug Class
5.5.3.2 Turkey
5.5.3.2.1 Market size and forecast, by Drug Class
5.5.3.3 South Africa
5.5.3.3.1 Market size and forecast, by Drug Class
5.5.3.4 Rest of LAMEA
5.5.3.4.1 Market size and forecast, by Drug Class
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 Azurity Pharmaceuticals
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 Johnson and Johnson
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 medicure
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 NeurOp
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 orexo ab
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Pfizer, Inc.
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 Pharmaxis, Ltd.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 Sun Pharmaceutical Industries Ltd.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 teva pharmaceutical industries ltd.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 Vitrais, Inc
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
TABLE 2. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OPIOID ANALGESIC, BY REGION , 2020-2030,($MILLION)
TABLE 3. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OPIOID ANALGESIC BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR CALCIUM CHANNEL BLOCKER, BY REGION , 2020-2030,($MILLION)
TABLE 5. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET CALCIUM CHANNEL BLOCKER BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR ANTICONVULSANT, BY REGION , 2020-2030,($MILLION)
TABLE 7. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET ANTICONVULSANT BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR STOOL SOFTENER, BY REGION , 2020-2030,($MILLION)
TABLE 9. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET STOOL SOFTENER BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OSMOTIC AGENTS/DIURETICS, BY REGION , 2020-2030,($MILLION)
TABLE 11. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OSMOTIC AGENTS/DIURETICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OTHER DRUGS, BY REGION , 2020-2030,($MILLION)
TABLE 13. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OTHER DRUGS BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
TABLE 16. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 18. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 19. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 20. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
TABLE 21. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 23. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 24. UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 25. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 26. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 27. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
TABLE 28. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 30. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 31. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 32. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 33. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 34. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)
TABLE 35. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 36. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 37. TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 38. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 39. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)
TABLE 40.AZURITY PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 41.AZURITY PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 42.AZURITY PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 43.AZURITY PHARMACEUTICALS: NET SALES,
TABLE 44.AZURITY PHARMACEUTICALS: KEY STRATERGIES
TABLE 45.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 46.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 47.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 48.JOHNSON AND JOHNSON: NET SALES,
TABLE 49.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 50.MEDICURE: COMPANY SNAPSHOT
TABLE 51.MEDICURE: OPERATING SEGMENTS
TABLE 52.MEDICURE: PRODUCT PORTFOLIO
TABLE 53.MEDICURE: NET SALES,
TABLE 54.MEDICURE: KEY STRATERGIES
TABLE 55.NEUROP: COMPANY SNAPSHOT
TABLE 56.NEUROP: OPERATING SEGMENTS
TABLE 57.NEUROP: PRODUCT PORTFOLIO
TABLE 58.NEUROP: NET SALES,
TABLE 59.NEUROP: KEY STRATERGIES
TABLE 60.OREXO AB: COMPANY SNAPSHOT
TABLE 61.OREXO AB: OPERATING SEGMENTS
TABLE 62.OREXO AB: PRODUCT PORTFOLIO
TABLE 63.OREXO AB: NET SALES,
TABLE 64.OREXO AB: KEY STRATERGIES
TABLE 65.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 66.PFIZER, INC.: OPERATING SEGMENTS
TABLE 67.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 68.PFIZER, INC.: NET SALES,
TABLE 69.PFIZER, INC.: KEY STRATERGIES
TABLE 70.PHARMAXIS, LTD.: COMPANY SNAPSHOT
TABLE 71.PHARMAXIS, LTD.: OPERATING SEGMENTS
TABLE 72.PHARMAXIS, LTD.: PRODUCT PORTFOLIO
TABLE 73.PHARMAXIS, LTD.: NET SALES,
TABLE 74.PHARMAXIS, LTD.: KEY STRATERGIES
TABLE 75.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 76.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 77.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 78.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 79.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 80.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 81.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 82.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 83.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 84.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 85.VITRAIS, INC: COMPANY SNAPSHOT
TABLE 86.VITRAIS, INC: OPERATING SEGMENTS
TABLE 87.VITRAIS, INC: PRODUCT PORTFOLIO
TABLE 88.VITRAIS, INC: NET SALES,
TABLE 89.VITRAIS, INC: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET SEGMENTATION
FIGURE 2.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
FIGURE 3.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,BY DRUG CLASS,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF OPIOID ANALGESIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANT ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF STOOL SOFTENER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OSMOTIC AGENTS/DIURETICS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER DRUGS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)
FIGURE 18.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY REGION,2020
FIGURE 19.U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 20.CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 21.MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 22.GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 23.FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 24.UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 25.ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 26.REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 27.JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 28.CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 29.AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 30.INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 31.REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 32.BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 33.TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 34.SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 35.REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40.COMPETITIVE DASHBOARD
FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 42.AZURITY PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 43.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
FIGURE 44.MEDICURE.: NET SALES ,($MILLION)
FIGURE 45.NEUROP.: NET SALES ,($MILLION)
FIGURE 46.OREXO AB.: NET SALES ,($MILLION)
FIGURE 47.PFIZER, INC..: NET SALES ,($MILLION)
FIGURE 48.PHARMAXIS, LTD..: NET SALES ,($MILLION)
FIGURE 49.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
FIGURE 51.VITRAIS, INC.: NET SALES ,($MILLION)

ページTOPに戻る

Table of Contents

Summary

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $323.51 million in 2020, and is projected to reach $456.31 million by 2030, registering a CAGR of 3.6% from 2021 to 2030.
Aneurysmal subarachnoid hemorrhage (aSAH) is a condition in which brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, which leads to paralysis, coma, or even death. The National Institutes of Health (NIH) stated that aSAH is a global health concern, with high fatality and permanent disability rates.
The main symptoms of aSAH include severe headache, nausea, vomiting, stiff neck, photophobia, blurred vision, loss of consciousness, and seizures. The diagnosis process of aSAH includes computed tomography (CT), lumbar puncture, angiogram, and magnetic resonance imaging (MRI).
The major factors that drives the global aSAH market are rise in prevalence of diseases such as stroke & hypertension, and surge in geriatric population. In addition, lifestyle that include increase in alcohol consumption and smoking increase risk of aSAH, which, in turn, stimulates the market growth. However, associated side effects of drugs and medication consumed during the treatment of aSAH restrain the market growth. Furthermore, increase in awareness regarding the treatment of aSAH is expected to provide numerous opportunities for the market growth in future.
The aSAH market is segmented on the basis of drug class and region. On the basis of drug class, the market is segmented into opioid analgesics, calcium channel blockers, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market.
Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity increase demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the product demand .
The major players operating in the global aSAH drugs market are Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.

KEY BENEFITS FOR STAKEHOLDERS
The report provides in-depth analysis of the global ASAH Drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ASAH Drugs market growth.
KEY MARKET SEGMENTS
#By Drug Class
##Opioid Analgesic
##Calcium Channel Blocker
## Anticonvulsant
##Stool Softener
##Osmotic agents/diuretics
##Other Drugs
#By Region
##North America
###U.S.
###Canada
###Mexico
##Europe
###Germany
###France
###UK
###Italy
###Spain
###Rest of Europe
##Asia-Pacific
###Japan
###China
###Australia
###India
###South Korea
###Rest of Asia-Pacific
##LAMEA
###Brazil
###Saudi Arabia
###South Africa
###Rest of LAMEA
List of key players profiled in the report:
• Azurity Pharmaceuticals
• Johnson & Johnson
• MediCure
• NeurOp
• Orexo AB
• Pfizer, Inc.
• Pharmaxis, Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vitrais, Inc.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

動脈瘤性くも膜下出血治療薬市場：薬物クラス別（オピオイド鎮痛剤、カルシウム拮抗剤、抗けいれん剤、便軟化剤、浸透圧剤/利尿剤、その他の薬物）。世界の機会分析および産業予測、2020-2030年

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?